Sangamo Therapeutics (SGMO)
OTHER OTC:SGMO
Want to see SGMO full AI Analyst Report?
SGMO Stock Chart & Stats
$0.26
-$0.13(-9.49%)
At close: 4:00 PM EST
$0.26
-$0.13(-9.49%)
Day’s Range― - ―
52-Week Range$0.10 - $0.77
Previous CloseN/A
Volume2.84M
Average Volume (3M)7.65M
Market Cap
$70.43M
Enterprise Value$65.70M
Total Cash (Recent Filing)$27.59M
Total Debt (Recent Filing)$19.33M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 11, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding414,288,850
10 Day Avg. Volume4,237,466
30 Day Avg. Volume7,646,780
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.25
Price to Sales (P/S)2.98
P/FCF Ratio-1.21
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue1.90
Enterprise Value/Gross Profit1.90
Enterprise Value/Ebitda-0.56
Forecast
1Y Price Target
$2.00Price Target Upside669.23% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$35.67M
Bulls Say, Bears Say
Bulls Say
Regulatory Clarity For ST-920FDA agreement on an accelerated approval endpoint and acceptance of 104‑week eGFR as confirmatory evidence materially reduces regulatory uncertainty for ST‑920. That lowers the incremental trial burden and timeline risk, improving the program's long‑term probability of approval and its attractiveness to partners and payers.
Durable Clinical Efficacy & SafetyReported multi‑year durability and a favorable safety profile suggest sustained biological effect from a one‑time or limited administration. Durable benefit and safety support stronger commercial prospects, potential for premium pricing, improved payer acceptance, and a structural differentiation versus chronic enzyme replacement therapies.
Platform Tech And Scientific VisibilityRepeated scientific presentations and platform progress (zinc‑finger epigenetic regulation, MINT targeted integration) indicate meaningful proprietary capabilities. A robust platform increases licensing and partnership optionality, creates durable IP leverage across multiple indications, and supports long‑term R&D productivity.
Bears Say
Heavy And Persistent Cash BurnSustained ~-$90M TTM operating and free cash outflows imply substantial runway pressure absent product revenue. Persistent cash burn forces frequent external financing, heightening dilution risk, potentially delaying clinical or regulatory milestones, and making multi‑year execution dependent on successful capital raises.
Negative Stockholders' EquityNegative shareholders' equity signals a materially weakened balance sheet despite modest nominal debt. This erodes financial flexibility, restricts borrowing capacity, increases lender/investor scrutiny, and raises the probability of dilutive balance‑sheet repairs that can impair long‑term shareholder value and strategic optionality.
Listing And Funding UncertaintyA NASDAQ delisting determination and OTCQB transition reduce market liquidity and investor access, making capital raises more difficult and expensive. Coupled with explicit going‑concern statements and management reliance on external financing, this elevates execution risk for BLA completion, commercialization, and partnership deals.
Sangamo Therapeutics News
SGMO FAQ
What was Sangamo Therapeutics’s price range in the past 12 months?
Sangamo Therapeutics lowest stock price was $0.10 and its highest was $0.77 in the past 12 months.
What is Sangamo Therapeutics’s market cap?
Sangamo Therapeutics’s market cap is $70.43M.
When is Sangamo Therapeutics’s upcoming earnings report date?
Sangamo Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 54 days.
How were Sangamo Therapeutics’s earnings last quarter?
Sangamo Therapeutics released its earnings results on May 14, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of $0.005 by -$0.085.
Is Sangamo Therapeutics overvalued?
According to Wall Street analysts Sangamo Therapeutics’s price is currently Undervalued.
Does Sangamo Therapeutics pay dividends?
Sangamo Therapeutics does not currently pay dividends.
What is Sangamo Therapeutics’s EPS estimate?
Sangamo Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Sangamo Therapeutics have?
Sangamo Therapeutics has 414,288,850 shares outstanding.
What happened to Sangamo Therapeutics’s price movement after its last earnings report?
Sangamo Therapeutics reported an EPS of -$0.08 in its last earnings report, missing expectations of $0.005. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sangamo Therapeutics?
Currently, no hedge funds are holding shares in SGMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sangamo Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (669.23% Upside)
$2.00 (669.23% Upside)
Hedge Fund Trend
Decreased
By 321.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $103.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.70%
12-Months-Change
Fundamentals
Return on Equity
6686.36%
Trailing 12-Months
Asset Growth
-30.41%
Trailing 12-Months
Company Description
Sangamo Therapeutics
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on transforming patient lives through the development of genomic medicines. The company leverages advanced platform technologies including gene therapy, cell therapy, genome editing, and genome regulation to achieve its objectives. A cornerstone of Sangamo's approach is its proprietary zinc finger protein (ZFP) technology platform. This platform facilitates the creation of zinc finger nucleases, which are specialized proteins capable of precisely altering DNA sequences by either inserting or inactivating specific genes. Furthermore, it produces ZFP transcription factors, proteins designed to modulate (increase or decrease) gene expression. Sangamo has a robust clinical pipeline, with key programs progressing through various stages. SB-525 is currently in the Phase III AFFINE clinical trial for the treatment of hemophilia A. Their gene therapy candidate, ST-920, is undergoing Phase I/II STAAR clinical trials for Fabry disease, while the cell therapy SAR445136 is being evaluated in Phase I/II PRECIZN-1 clinical trials for sickle cell disease. The company's development efforts also extend to other therapeutic areas, including TX200, a chimeric antigen receptor for addressing HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy targeting cancer; ST-501 for tauopathies; and ST-502, which is aimed at treating synucleinopathies like Parkinson's disease and other neuromuscular disorders. Sangamo has established numerous collaborative and strategic partnerships with leading entities such as Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and the California Institute for Regenerative Medicine. Established in 1995, the company was initially known as Sangamo BioSciences, Inc. It subsequently adopted its current name, Sangamo Therapeutics, Inc., in January 2017. The corporate headquarters are situated in Brisbane, California.
SGMO Company Deck
SGMO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights meaningful clinical and regulatory progress for ST-920 (rolling BLA, FDA affirmation of 2-year confirmatory endpoint, durable long-term patient data) and continued advancement across neurology programs and platform technologies. However, material near-term risks center on capital availability and a NASDAQ delisting determination that forced a transition to the OTCQB market. Progress on regulatory and scientific fronts is balanced by significant financing and market-listing challenges that could impact execution and timing.View all SGMO earnings summariesSGMO Stock 12 Month Forecast
Average Price Target
$2.00
▲(669.23% Upside)
Technical Analysis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Elicio Therapeutics
―
Caribou Biosciences
―
Ownership Overview
0.94% Insiders
5.50% Mutual Funds
11.70% Other Institutional Investors
81.87% Public Companies and
Individual Investors